AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Running, not enrolling · Phase 1

Conditions studied: Tumor, Cancer

In brief

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.

Key facts

Study ID

NCT00463814

Run by

AstraZeneca

People needed

58

Starts

2007-03-08

Expected to finish

2027-03-26

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• cancer which is refractory to standard therapies
• World Health Organization (WHO) performance status 0 to 2
• evidence of post-menopausal status or negative pregnancy test

You may not qualify if…

• Radiotherapy/chemotherapy within 21 days prior to entry
• brain metastases/spinal cord compression unless stable off steroids/anticonvulsants
• evidence of severe/uncontrolled systemic disease
• participated in an investigational drug study within 30 days

Where it is running

• Research Site — Aurora, Colorado, United States
• Research Site — Nijmegen, Netherlands
• Research Site — Utrecht, Netherlands
• Research Site — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.